PASER Trial: A Randomized, Controlled, Non-Inferiority Study

The PASER trial was from our colleagues in the Netherlands, and the same Netherlands with maybe the most heartbreaking loss I've ever seen in a World Cup game against Argentina. Adult patients were eligible for enrollment if their platelet count was between 10,000 and 50,000, and their INR was less than three. The study certainly supports the transfusion of platelets in those thromosinopenic patients, getting a central venous catheter placed. But this study saw much higher rates of bleeding than previous studies.